The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States

American Journal of Obstetrics and Gynecology

Volumn 216, Issue 3, 2017, Pages 270.e1-270.e9

  Hanley, Gillian Elizabeth ^a   McAlpine, Jessica Nell ^a   Pearce, Celeste Leigh ^b   Miller, Dianne ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

bilateral salpingectomy; hysterectomy; ovarian cancer prevention; tubal sterilization; United States

Indexed keywords

ADULT; AGED; ARTICLE; BILATERAL SALPINGECTOMY; CANCER PREVENTION; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; HYSTERECTOMY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CANCER; PATIENT SAFETY; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SALPINGECTOMY; SURGICAL INFECTION; UNITED STATES; UTERINE TUBE LIGATION; UTERINE TUBE STERILIZATION; VERY ELDERLY; ADOLESCENT; ADVERSE EFFECTS; OVARIAN NEOPLASMS; PROCEDURES; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; OVARIAN NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SALPINGECTOMY; STERILIZATION, TUBAL; UNITED STATES; YOUNG ADULT;

EID: 85007564359     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2016.10.035     Document Type: Article

References (29)

1. 1 Rosenthal, A.N., Fraser, L., Manchanda, R., et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 31 (2013), 49–57.
2. 2 Buys, S.S., Partridge, E., Black, A., et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305 (2011), 2295–2303.
3. 3 Kobayashi, H., Yamada, Y., Sado, T., et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 18 (2008), 414–420.
4. 4 Menon, U., Gentry-Maharaj, A., Hallett, R., et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS). Lancet Oncol 10 (2009), 327–340.
5. 5 Menon, U., Ryan, A., Kalsi, J., et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom collaborative trial of ovarian cancer screening. J Clin Oncol 33 (2015), 2062–2071.
6. 6 Kobel, M., Kalloger, S.E., Huntsman, D.G., et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29 (2010), 203–211.
7. 7 Gao, F.F., Bhargava, R., Yang, H., Li, Z., Zhao, C., Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?. Hum Pathol 44 (2013), 1534–1543.
8. 8 Crum, C.P., Drapkin, R., Miron, A., et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19 (2007), 3–9.
9. 9 Karst, A.M., Levanon, K., Drapkin, R., Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A 108 (2011), 7547–7552.
10. 10 Singh, N., Gilks, C.B., Wilkinson, N., McCluggage, W.G., Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. Histopathology 67 (2015), 331–337.
11. 11 The Society of Gynecologic Oncology of Canada. GOC statement regarding salpingectomy and ovarian cancer prevention. 2011. Available at https://g-o-c.org/wp-content/uploads/2015/09/7GOCStmt_2011Sep_SalpOvCa_EN.pdf. Accessed November 8, 2016.
12. 12 Society of Gynecologic Oncology. Salpingectomy for ovarian cancer. SGO Clinical practice statement. 2013. Available at https://www.sgo.org/clinical-practice/guidelines/sgo-clinical-practice-statement-salpingectomy-for-ovarian-cancer-prevention/. Accessed November 8, 2016.
13. 13 American College of Obstetrics and Gynecology. Salpingectomy for ovarian cancer prevention. Committee opinion no. 620. Obstet Gynecol 125 (2015), 279–281.
14. 14 Hicks-Courant, K.D., Growth in salpingectomy rates in the United States since 2000. Am J Obstet Gynecol 215 (2016), 666–667.
15. 15 Mikhail, E., Salemi, J.L., Mogos, M.F., Hart, S., Salihu, H.M., Imudia, A.N., National trends of adnexal surgeries at the time of hysterectomy for benign indication, United States, 1998-2011. Am J Obstet Gynecol 213 (2015), 713.e1–713.e13.
16. 16 Houchens, R.L., Ross, D.N., Elixhauser, A., Jiang, J., Nationwide Inpatient Sample redesign: final report. 2014, Agency for Healthcare Research and Quality, Maryland.
17. 17 University of British Columbia Board of Governors. Research Involving Human Participants. Policy no. 89. 2012. Vancouver, BC, Canada.
18. 18 McAlpine, J.N., Hanley, G.E., Woo, M.M., et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 210 (2014), 471.e1–471.e11.
19. 19 Wright, J.D., Herzog, T.J., Tsui, J., et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol 122 (2013), 233–241.
20. 20 Parker, W.H., Broder, M.S., Chang, E., et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 113 (2009), 1027–1037.
21. 21 Parker, W.H., Feskanich, D., Broder, M.S., et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol 121 (2013), 709–716.
22. 22 Hanley, G., McAlpine, J., Kwon, J., Mitchell, G., Opportunistic salpingectomy for ovarian cancer prevention. Gynaecol Oncol Res Pract 2 (2015), 1–9.
23. 23 Gill, S.E., Mills, B.B., Physician opinions regarding elective bilateral salpingectomy with hysterectomy and for sterilization. J Minim Invasive Gynecol 20 (2013), 517–521.
24. 24 Lessard-Anderson, C.R., Handlogten, K.S., Molitor, R.J., et al. Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol 135 (2014), 423–427.
25. 25 Madsen, C., Baandrup, L., Dehlendorff, C., Kjaer, S.K., Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand 94 (2015), 86–94.
26. 26 Falconer, H., Yin, L., Gronberg, H., Altman, D., Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 107 (2015), 1–6.
27. 27 Yoon, S.H., Kim, S.N., Shim, S.H., Kang, S.B., Lee, S.J., Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis. Eur J Cancer 55 (2016), 38–46.
28. 28 Morelli, M., Venturella, R., Mocciaro, R., et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol 129 (2013), 448–451.
29. 29 Findley, A.D., Siedhoff, M.T., Hobbs, K.A., et al. Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. Fertil Steril 100 (2013), 1704–1708.